17-Oximino-5-androsten-3β-yl esters: Synthesis, antiproliferative activity, acute toxicity, and effect on serum androgen level

Medicinal Chemistry Research

Volumn 20, Issue 7, 2011, Pages 817-825

  Dhingra, Neelima ^a   Bhardwaj, Tilak Raj ^a,b   Mehta, Neeraj ^a   Mukhopadhyay, Tapas ^c   Kumar, Ashok ^c   Kumar, Manoj ^a  

^a PANJAB UNIVERSITY   (India)

^b ISF COLLEGE OF PHARMACY   (India)

^c PANJAB UNIVERSITY   (India)

Author keywords

5 Alpha reductase enzyme; Androgen; Benign prostatic hyperplasia; Dihydrotestosterone; Steroids

Indexed keywords

17 OXIMINO 5 ANDROSTEN 3BETA YL 4 AMINOBENZOATE; 17 OXIMINO 5 ANDROSTEN 3BETA YL 4 CHLOROBENZOATE; 17 OXIMINO 5 ANDROSTEN 3BETA YL 4 HYDROXYBENZOATE; 17 OXIMINO 5 ANDROSTEN 3BETA YL 4 METHOXYBENZOATE; 17 OXIMINO 5 ANDROSTEN 3BETA YL 4 METHYLBENZOATE; 17 OXIMINO 5 ANDROSTEN 3BETA YL 4 NITROBENZOATE; 17 OXIMINO 5 ANDROSTEN 3BETA YL 4 PHENYLACETATE; 17 OXIMINO 5 ANDROSTEN 3BETA YL BENZOATE; 17 OXIMINO 5 ANDROSTEN 3BETA YL CHLOROACETATE; 17 OXIMINO 5 ANDROSTEN 3BETA YL PHENOXYACETATE; ANDROGEN; ANTINEOPLASTIC AGENT; FINASTERIDE; STEROID; UNCLASSIFIED DRUG;

ANDROGEN BLOOD LEVEL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LC 50; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROSTATE CANCER;

EID: 80054762457     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9393-3     Document Type: Article

References (25)

1. Andersson S, Russell DW (1990) Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductase. Proc Natl Acad Sci USA 87:3640-3644.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474-479 (Pubitemid 14026148)
3. Brady SF, Pawluczyk JM, Lumma PK, Feng DM, Wai JM, Jones R, DeFeo-Jones D, Wong BK, Miller-Stein C, Lin JH, Oliff A, Freidinger RM, Garsky VM (2002) Design and synthesis of a prodrug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systematic toxicity. J Med Chem 45:4706-4715
4. Bruchoksky N, Sadar MD, Akakura K, Goldenberg SL, Matsuoka K, Rennie PS (1996) Characterization of 5 alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 59:397-404 (Pubitemid 27037906)
5. Bullock TL, Andriole GL (2006) Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs 11:111-123
6. Cabeza M, Heuze I, Bratoeff E, Murillo E, Ramirez E, Lira A (2001) New progesterone esters as 5a-reductases inhibitors. Chem Pharm Bull (Tokyo) 49:1081-1084 (Pubitemid 32847511)
7. Chen Li X, Singh C, Labrie SM (1994) The enzyme and inhibitors of 4-ene-3-oxosteroids 5-alpha. Steroids 60:430-441
8. Cholody WM, Cholody TK, Hollingshead MG, Haripraksha HK, Michejda CJ (2005) A new synthetic agent with potent but selective cytotoxic activity against cancer. J Med Chem 48:4474-4481 (Pubitemid 40884949)
9. Garsky VN, Lumma P, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, Frendinger RM (2001) The synthesis of a prodrug of doxorubicin designed to provide reduced systematic toxicity and greater target efficacy. J Med Chem 44:4216-4224 (Pubitemid 33095328)
10. Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Njar VC (2005) A new simple and high yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem 48:5047-5057
11. Gerhard VH (2002) Drug discovery and evaluation: Pharmacological assays, 2nd edn. Springer-Verlag, New York
12. Gududuru V, Hurh E, Dalton JT, Miller DD (2005) Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer. J Med Chem 48:2584-2588 (Pubitemid 40516447)
13. Hartmann RW, Hector M, Haidar S, Ehmer PB, Reichert W, Jose J (2000) Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17a-hydroxylase/C17-20-lyase) and 5areductase types 1 and 2. J Med Chem 43:4266-4277
14. Hershberg EB (1948) Regeneration of steroid ketones from their semicarbazones with pyruvic acid. J Org Chem 13:542-546
15. Isaacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2:33-50 (Pubitemid 20075619)
16. Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB (2001) Design, synthesis and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 44:4696-4703 (Pubitemid 33144479)
17. Kenny B, Blagg SJ, Fox D (1997) Options in the treatment of benign prostatic hyperplasia. J Med Chem 40:1293-1312
18. March J (2001) Advanced organic chemistry, 5th edn. Wiley, New York
19. Mason HL, Kepler EJ (1945) Isolation of steroids from the urine of patients with adrenal cortical tumors and adrenal cortical hyperplasia: A new 17-ketosteroid, androstane-3(a),11-diol-17-one. J Biol Chem 161:235-237
20. Mosmann TJ (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Immunol Methods 65:55-63
21. Occhiato EG, Guarna A, Danza G, Serio M (2004) Selective nonsteroidal inhibitors of 5a-reductase type-1. J Steroid Biochem Mol Biol 88:1-16 (Pubitemid 38326593)
22. Perez-Stable C (2006) 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett 231:49-64 (Pubitemid 41779453)
23. Regan EM, Hayes FN (1956) 17-and 17a-Aza-D-homosteroids. J Am Chem Soc 78:639-643
24. Stahl F, Gotz F, Dorner G (1984) Plasma testosterone levels in rats under various conditions. Exp Clin Endorcinol 84:277-284 (Pubitemid 15220746)
25. Valasinas A, Sarkar A, Reddy VK, Marton LJ, Basu HS, Frydman B (2001) Conformationally restricted analogues of 1N, 14N-bisethylhomospermine (BE-4 -4 -4 -): Synthesis and growth inhibitory effects on human prostate cancer cells. J Med Chem 44:390-403 (Pubitemid 32113585)